Abstract
Purpose: To study changes in three tumor markers before and after combination treatment with pemetrexed and platinum, and evaluate the short-term therapeutic effectiveness of the treatment in advanced lung adenocarcinoma (ALA) subjects.
 Method: Patients with ALA (n =120) admitted to JinHua Municipal Central Hospital from January 2017 to May 2018 were selected as the research subjects. According to the results of chemotherapy, they were divided into two groups: significantly-reduced tumor volume group (90 cases), and nonsignificantly-reduced tumor volume group (21 cases). The two groups were treated with chemotherapy using a combination of pemetrexed and cisplatin. The levels of CEA, CA125 and CYFRA21-1 before and after chemotherapy were assayed to determine their relationship with short-term therapy effectiveness.
 Result: Overall analysis of tumor markers in the 120 patients with ALA showed statistically significant reduction in overall tumor marker levels before and after chemotherapy (p < 0.05). At the end of chemotherapy, the tumor markers were markedly reduced in subjects with significant tumor volume, and there was statistical difference between the two groups before chemotherapy (p < 0.05). Changes in CEA, CA125 and CYFRA21-1 were positively correlated with the chemotherapeutic effects on patients with ALA.
 Conclusion: In ALA patients treated with pemetrexed and platinum, changes in serum CEA, CA125 and CYFRA21-1 profiles before and after treatment depend on the effect of chemotherapy, and they are reliable for prediction of short-term therapeutic efficacy.
Highlights
Cancer of the lung cancer is the most frequently occurring malignant tumor in the world, and its incidence is rising
This study was performed in patients with advanced lung adenocarcinoma (ALA) who received pemetrexed plus cisplatin with the aim of comparing the serum levels of CEA, CA125 and CYFRA21-1
In the group of non-significantly reduced tumor volume, the CEA, CA125 and CYFRA21-1 profiles after chemotherapy were comparable with their corresponding values before chemotherapy
Summary
Cancer of the lung cancer is the most frequently occurring malignant tumor in the world, and its incidence is rising. Lung cancer comprises small cell lung cancer and non-small cell lung cancer. Lung cell adenocarcinoma belongs to the category of non-small cell lung cancer. A variety of tumor markers are associated with lung cancer. These tumor markers reflect the occurrence, classification, therapeutic effects, and prognosis of lung cancer subjects [1]. This study was performed in patients with ALA who received pemetrexed plus cisplatin with the aim of comparing the serum levels of CEA, CA125 and CYFRA21-1. The predictive value of these tumor markers was determined, with a view of providing a basis for the treatment of patients with ALA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
